Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

Jeffrey A. Allen, Deborah F. Gelinas, Miriam Freimer, M. Chris Runken, Gil I. Wolfe

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.

Original languageEnglish (US)
Article number116497
JournalJournal of the Neurological Sciences
StatePublished - Jan 15 2020

Bibliographical note

Publisher Copyright:
© 2019 The Authors


  • Chronic inflammatory demyelinating polyneuropathy
  • Intravenous immunoglobulin
  • Maintenance therapy
  • Route of administration comparison
  • Subcutaneous immunoglobulin


Dive into the research topics of 'Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?'. Together they form a unique fingerprint.

Cite this